Esterases from the Seeds of an Edible Legume, <i> Phaseolus vulgaris</i> L.; Variability and Stability during Germination
- 1 Department of Biotechnology, PES Institute of Technology, Bangalore, India
- 2 Department of Biotechnology, PES Institute of Technology, Bangalore, India
- 3 Department of Biotechnology, PES Institute of Technology, Bangalore, India
- 4 Department of Biotechnology, PES Institute of Technology, Bangalore, India
- 5 Department of Biochemistry, Bangalore University, Bangalore, India
- 6 Department of Biotechnology, PES Institute of Technology, Bangalore, India
Abstract
The total protein and esterase were isolated from the seeds of Red Kidney beans ( Phaseolus vulgaris ). The crude protein content was observed as 15%. The germination of seeds of red kidney bean has been carried out and change in the total protein content and esterase activity was monitored. The protein content was decreased from 15% (24 hours) to 8% (144 hours) during germination. The socked seeds and seedlings of all the days of germination exhibited esterase activity. Maximum ester hydrolyzing activity was observed o n 6th day of germination w hereas as lowest ester hydrolyzing activity was observed 2nd day germination. Native PAGE was carried out and esterase banding pattern for two different artificial substrates was studied. The esterase banding pattern in presence of 1-Napthyl acetate showed the presence of 4 esterolytic bands while 2 esterolytic bands were observed in presence of 2-Napthyl acetate .
- K. S. Chandrashekharaiah, K. R. S. Murthy, N. R. Swamy, “Carboxylesterases (Purification and Characterization),” Verlag: LAP Lambert Academic Publishing GmbH and Co. KG, Saarbrücken, 2011, pp. 13-150.
- M. R. Redinbo and P. M. Potter, “Mammalian Carboxylesterases: From Drug Targets to Protein Therapeutics,” Drug Discovery Today, Vol. 10, No. 5, 2005, pp. 313-325. doi:10.1016/S1359-6446(05)03383-0
- P. M. Potter and R. M. Wadkins, “Carboxylesterases: Detoxifying Enzymes and Targets for Drug Therapy,” Current Medicinal Chemistry, Vol. 13, No. 9, 2006, pp. 1045-1054. doi:10.2174/092986706776360969
- F. M. Willams, “Clinical Significance of Esterases in Man,” Clinical Pharmacokinetics, Vol. 10, No. 5, 1985, pp. 392-403. doi:10.2165/00003088-198510050-00002
- B. K. Tang and W. Kalow, “Variable Activation of Lovastatin by Hydrolytic Enzymes in Human Plasma and Liver,” European Journal of Clinical Pharmacology, Vol. 47, No. 5, 1995, pp. 449-451. doi:10.1007/BF00196860
- D. Shi, J. Yang, D. Yang, L. Edward, L. Cluyse, C. Black, L. You, F. Akhlaghi and B. Yan, “Anti-Influenza Prodrug Oseltamivir Is Activated by Carboxylesterase Human Carboxylesterase 1, and the Activation Is Inhibited by Antiplatelet Agent Clopidogrel,” The Journal of Pharmacology, Vol. 319, No. 3, 2006, pp. 1477-1484.
- J. Zhang, J. C. Burnell, N. Dumaual and W. F. Bosron, “Binding and Hydrolysis of Human Liver Carboxylesrerase hCE-1,” Journal of Pharmacology, Vol. 290, No. 1, 1999, pp. 314-318.
- E. V. Pindel, N. Y. Kedishvili, T. R. Abraham, M. R. Brzezinski, J. Zhang, R. A. Dean and W. F. Bosron, “Purification and Cloning of a Human Liver Carboxylesterase (hCE-2) That Catalyzes the Hydrolysis of Cocaine and Heroin,” Journal of Biological Chemistry, Vol. 272, 1997, pp. 14769-14775. doi:10.1074/jbc.272.23.14769
- N. Bodor and P. Buchwald, “Soft Drug Design: General Principle and Recent Applications,” Medicinal Research Reviews, Vol. 20, No. 1, 2000, pp. 58-101. doi:10.1002/(SICI)1098-1128(200001)20:1 3.0.CO;2-X
- N. Bodor and P. Buchwald, “Retrometabolism-Based Drug Design and Targeting,” In: D. J. Abraham, Ed., Drug Discovery and Drug Development Burger’s Medicinal Chemistry and Drug Discovery, 6th Edition, John Wiley and Sons, New York, 2003, pp. 533-608.
- N. Bodor and P. Buchwald, “Designing Safer (Soft) Drugs by Avoiding the Formation of Toxic and Oxidative Metabolites,” Molecular Biotechnology, Vol. 26, No. 2, 2000, pp. 123-132. doi:10.1385/MB:26:2:123